<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tian R</submitter><funding>National Cancer Institute</funding><funding>National Institutes of Health through Cancer Center</funding><funding>NCI NIH HHS</funding><funding>Cancer Prevention Research Institute of Texas</funding><pagination>77-83</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5509529</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>132</volume><pubmed_abstract>Mounting evidence supports a mechanistic link between inflammation and cancer, especially colon cancer. ALOX15 (15-lipoxygenase-1) plays an important role in the formation of key lipid mediators (e.g., lipoxins and resolvins) to terminate inflammation. ALOX15 expression is downregulated in colorectal cancer (CRC). Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis. ALOX15 suppressed the TNF-α, IL-1β/NF-κB, and IL-6/STAT3 sign</pubmed_abstract><journal>Prostaglandins &amp; other lipid mediators</journal><pubmed_title>ALOX15 as a suppressor of inflammation and cancer: Lost in the link.</pubmed_title><pmcid>PMC5509529</pmcid><funding_grant_id>R01 CA195686</funding_grant_id><funding_grant_id>CA016672</funding_grant_id><funding_grant_id>R01-CA 195686</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>RP140224</funding_grant_id><funding_grant_id>R01 CA206539</funding_grant_id><funding_grant_id>R01-CA 206539</funding_grant_id><funding_grant_id>RP150195</funding_grant_id><pubmed_authors>Jaoude J</pubmed_authors><pubmed_authors>Shureiqi I</pubmed_authors><pubmed_authors>Zuo X</pubmed_authors><pubmed_authors>Tian R</pubmed_authors><pubmed_authors>Colby J</pubmed_authors><pubmed_authors>Mao F</pubmed_authors></additional><is_claimable>false</is_claimable><name>ALOX15 as a suppressor of inflammation and cancer: Lost in the link.</name><description>Mounting evidence supports a mechanistic link between inflammation and cancer, especially colon cancer. ALOX15 (15-lipoxygenase-1) plays an important role in the formation of key lipid mediators (e.g., lipoxins and resolvins) to terminate inflammation. ALOX15 expression is downregulated in colorectal cancer (CRC). Intestinally-targeted transgenic expression of ALOX15 in mice inhibited dextran sodium sulfate-induced colitis from promoting azoxymethane- induced colorectal tumorigenesis, demonstrating that ALOX15 can suppress inflammation-driven promotion of carcinogen-induced colorectal tumorigenesis and therefore ALOX15 downregulation during tumorigenesis is likely to enhance the link between colitis and colorectal tumorigenesis. ALOX15 suppressed the TNF-α, IL-1β/NF-κB, and IL-6/STAT3 sign</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2025-04-19T22:40:50.646Z</modification><creation>2019-03-26T23:53:00Z</creation></dates><accession>S-EPMC5509529</accession><cross_references><pubmed>28089732</pubmed><doi>10.1016/j.prostaglandins.2017.01.002</doi></cross_references></HashMap>